POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
Financing co-led by Deerfield Management and Janus Henderson Investors, with additional new and...June 9, 2021 -- RemeGen Co., Ltd. (RemeGen, 9995.HK) announces that disitamab vedotin (RC48,...May 26, 2021 08:00 AM Eastern Daylight Time WILMINGTON, Del.--(BUSINESS WIRE)--NiKang...CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Rgenta Therapeutics announced today that it...PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics ...SHANGHAI/SUZHOU, China, May 13, 2021. Elpiscience Biopharma, a clinical stage biopharma focusing...Shanghai, China. May 10, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a...April 26, 2021--- Scivita Medical Technology Co., Ltd. ("Scivita Medical") today announced that...More Posts
Company
Shanghai
Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong
US
2730 Sand Hill Road, Suite 130, Menlo Park, CA
copyright © 2018 Lilly Asia Ventures all rights reserved.
沪公网安备 31010102005458号All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
http://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png